Alzheimer's disease (AD) and diabetes mellitus (DM) are related to abnormal changes in enzyme activity. While acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) are the primary targets in the treatment of Alzheimer's disease (AD), α-glucosidase (α-Gly) and α-amylase (α-Amy) enzymes are known for diabetes mellitus (DM). Here, benzenesulfonamide-based thiourea and thiazolidinone derivatives such as AChE, BChE, α-Gly, and α-Amy inhibitors were reported. The results revealed that compounds 1d and 2c showed promising AChE and BChE inhibition effects. Compound 2a was the most potent inhibitor against α-glycosidase and α-amylase, respectively. Molecular docking studies indicated that the lead compounds' binding energy values and molecular interactions were better than that of tacrine and acarbose. The most bioactive compounds may be considered potent leads for further studies.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.